Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.

[1]  Siddharth Singh,et al.  Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  L. Beaugerie,et al.  Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  F. Carrat,et al.  Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. , 2018, Gastroenterology.

[4]  L. Ohno-Machado,et al.  Annual Burden and Costs of Hospitalization for High‐Need, High‐Cost Patients With Chronic Gastrointestinal and Liver Diseases , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  M. Murad,et al.  Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease , 2018, Alimentary pharmacology & therapeutics.

[6]  J. Satsangi,et al.  Open: Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow‐up in the PYRAMID Registry , 2018, The American Journal of Gastroenterology.

[7]  Siddharth Singh,et al.  277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis , 2018 .

[8]  Siddharth Singh,et al.  Sa1711 - Real World Comparative Risk of Serious Infection with Adalimumab, Vedolizumab, and Infliximab in Patients with Inflammatory Bowel Disease , 2018 .

[9]  L. Ohno-Machado,et al.  Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases. , 2018, Inflammatory bowel diseases.

[10]  E. Loftus,et al.  Comparison of infliximab with adalimumab in 827 biologic‐naïve patients with Crohn's disease: a population‐based Danish cohort study , 2018, Alimentary pharmacology & therapeutics.

[11]  A. Gasbarrini,et al.  Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease , 2018, Clinical epidemiology.

[12]  C. Brensinger,et al.  Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease , 2018, The American Journal of Gastroenterology.

[13]  M. Murad,et al.  Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis , 2018, Alimentary pharmacology & therapeutics.

[14]  S. Bonovas,et al.  Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease , 2017, Clinical pharmacology and therapeutics.

[15]  Siddharth Singh,et al.  Comparison of Infliximab and Adalimumab in Biologic‐Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  Subrata Ghosh,et al.  Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn’s Disease Treated With Infliximab [Remicade®] or Conventional Therapy , 2016, Journal of Crohn's & colitis.

[17]  T. Matsui,et al.  Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. , 2016, Journal of Crohn's & colitis.

[18]  S. Bonovas,et al.  Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  J. Lewis,et al.  Crohn’s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab , 2016, The American Journal of Gastroenterology.

[20]  Siddharth Singh,et al.  Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  S. Saini,et al.  Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort , 2016, PloS one.

[22]  G. Rogler,et al.  The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease , 2016, PloS one.

[23]  H. Heien,et al.  Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis , 2016, Alimentary pharmacology & therapeutics.

[24]  T. Matsui,et al.  Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease , 2016, Journal of Crohn's & colitis.

[25]  P. Rutgeerts,et al.  The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.

[26]  A. Bitton,et al.  Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial , 2015, The Lancet.

[27]  P. Sedgwick,et al.  How to read a funnel plot in a meta-analysis , 2015, BMJ : British Medical Journal.

[28]  B. Pasternak,et al.  Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study , 2015, BMJ : British Medical Journal.

[29]  M. V. van Oijen,et al.  Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[30]  A. Cohen,et al.  Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. , 2014, Gastroenterology.

[31]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[32]  C. Bernstein,et al.  Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD , 2013, The American Journal of Gastroenterology.

[33]  C. Bombardier,et al.  Assessing Bias in Studies of Prognostic Factors , 2013, Annals of Internal Medicine.

[34]  W. Sandborn,et al.  Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry , 2012, The American Journal of Gastroenterology.

[35]  Jeffrey R Curtis,et al.  Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. , 2011, JAMA.

[36]  J. Andrews,et al.  Serious infections in patients with inflammatory bowel disease receiving anti‐tumor‐necrosis‐factor‐alpha therapy: An Australian and New Zealand experience , 2010, Journal of gastroenterology and hepatology.

[37]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[38]  S. Schneeweiss,et al.  Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections , 2009, Alimentary pharmacology & therapeutics.

[39]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[40]  P. Rutgeerts,et al.  Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study , 2007, Gut.

[41]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[42]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.